Stubbs Alderton & Markiles’ client Kairos Ventures led a Series B investment round for Actuate Therapeutics, a clinical stage biopharmaceutical company, raising $21.7 Million. Also participating in this round were DEFTA Partners, Tech Coast Angels, and existing investor Bios Partners.
To read the full press release visit here.
Stubbs Alderton & Markiles’ attorneys representing Kairos Ventures in this deal are Louis Wharton, Kelly Laffey, and David Stoops.
About Kairos Ventures
Kairos Ventures invests early, often during the formative stages of a company, and works closely with the world’s leading scientists to commercialize their technologies. Depending on the stage of development and the capital requirements of each venture, they make investments between $150,000 and $20 Million. While Kairos Ventures is hands-on they also recognize that it is the entrepreneurs’ sweat, hard work, and perseverance that will drive the growth of their companies. They strive to ensure that the founding team, who make the early sacrifices in pursuit of their venture, retain the majority of the ownership in their companies. In addition to providing early-stage capital, Kairos Ventures leverages their expertise and extensive network of professionals specializing in all disciplines required to build a successful company, including legal, finance, marketing, operations, business development, and HR. They provide these services to early-stage companies in their portfolio to allow the entrepreneurs to focus their energy on continuing to innovate and pushing the envelope in their respective fields.
For more information about our Venture Capital and Emerging Growth Practice , contact Louis Wharton at
